ΣΦ-4004

ΣΦ-4004 is an internal development code for a pharmaceutical candidate developed by Sigmapharm Laboratories. It is part of the company's pipeline of unique generic and branded products, which includes a series of candidates (ΣΦ-4001 through ΣΦ-4010) tracked through various stages of regulatory development, including feasibility, formulation, and preparation for Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) submissions. The candidate is characterized by "barrier-to-entry" properties, which typically refer to complexities in formulation, patent litigation, bioavailability, or stability that limit competition. As of the company's public disclosures, the specific active pharmaceutical ingredient (API), molecular target, and therapeutic indication for ΣΦ-4004 remain undisclosed.